Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis

Endogenous ligands of TLR4 promote unresolving tissue fibrosis: Implications for systemic sclerosis and its targeted therapy

(2018) Swati Bhattacharyya et al.   IMMUNOLOGY LETTERS

Systemic sclerosis

(2017) Christopher P Denton et al.   LANCET

Relaxin abrogates renal interstitial fibrosis by regulating macrophage polarization via inhibition of Toll-like receptor 4 signaling

(2017) Lei Chen et al.   Oncotarget

Positive Feedback Regulation between Transglutaminase 2 and Toll-Like Receptor 4 Signaling in Hepatic Stellate Cells Correlates with Liver Fibrosis Post Schistosoma japonicum Infection

(2017) Zhencheng Wen et al.   Frontiers in Immunology

Toll-Like Receptor-4 Signaling Drives Persistent Fibroblast Activation and Prevents Fibrosis Resolution in Scleroderma

(2017) Swati Bhattacharyya et al.   Advances in Wound Care

Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis

(2017) Norihiko Sakai et al.   Scientific Reports

Tenascin-C drives persistence of organ fibrosis

(2016) Swati Bhattacharyya et al.   Nature Communications

Identification of Optimal Mouse Models of Systemic Sclerosis by Interspecies Comparative Genomics

(2016) Jennifer L. Sargent et al.   Arthritis & Rheumatology

Systemic sclerosis

(2015) Yannick Allanore et al.   Nature Reviews Disease Primers

TAK-242, a Toll-Like Receptor 4 Antagonist, Protects against Aldosterone-Induced Cardiac and Renal Injury

(2015) Yide Zhang et al.   PLoS One

Fibrosis—a lethal component of systemic sclerosis

(2014) Yuen Yee Ho et al.   Nature Reviews Rheumatology

FibronectinEDA Promotes Chronic Cutaneous Fibrosis Through Toll-Like Receptor Signaling

(2014) S. Bhattacharyya et al.   Science Translational Medicine

Molecular Signatures in Skin Associated with Clinical Improvement during Mycophenolate Treatment in Systemic Sclerosis

(2013) Monique Hinchcliff et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Toll-Like Receptor 4 Signaling Augments Transforming Growth Factor-β Responses

(2012) Swati Bhattacharyya et al.   AMERICAN JOURNAL OF PATHOLOGY

Mechanisms of fibrosis: therapeutic translation for fibrotic disease

(2012) Thomas A Wynn et al.   NATURE MEDICINE

Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities

(2011) Swati Bhattacharyya et al.   Nature Reviews Rheumatology

A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*

(2010) Todd W. Rice et al.   CRITICAL CARE MEDICINE

TAKEDA-143242 Increased Survival Via Reduced Cytokines in Porcine Peritonitis

(2010) Roy D. Goldfarb et al.   JOURNAL OF SURGICAL RESEARCH

TAK-242 (Resatorvid), a Small-Molecule Inhibitor of Toll-Like Receptor (TLR) 4 Signaling, Binds Selectively to TLR4 and Interferes with Interactions between TLR4 and Its Adaptor Molecules

(2010) N. Matsunaga et al.   MOLECULAR PHARMACOLOGY

Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model

(2009) K Takashima et al.   BRITISH JOURNAL OF PHARMACOLOGY

Scleroderma

(2009) Armando Gabrielli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Standardized quantification of pulmonary fibrosis in histological samples

(2008) Ralf-Harto Hübner et al.   BIOTECHNIQUES